331 related articles for article (PubMed ID: 27336598)
1. Diagnostic Accuracy of PIK3CA Mutation Detection by Circulating Free DNA in Breast Cancer: A Meta-Analysis of Diagnostic Test Accuracy.
Zhou Y; Wang C; Zhu H; Lin Y; Pan B; Zhang X; Huang X; Xu Q; Xu Y; Sun Q
PLoS One; 2016; 11(6):e0158143. PubMed ID: 27336598
[TBL] [Abstract][Full Text] [Related]
2. Accuracy of analysis of cfDNA for detection of single nucleotide variants and copy number variants in breast cancer.
Yang X; Zhang K; Zhang C; Peng R; Sun C
BMC Cancer; 2019 May; 19(1):465. PubMed ID: 31101027
[TBL] [Abstract][Full Text] [Related]
3. Value of circulating cell-free DNA analysis as a diagnostic tool for breast cancer: a meta-analysis.
Lin Z; Neiswender J; Fang B; Ma X; Zhang J; Hu X
Oncotarget; 2017 Apr; 8(16):26625-26636. PubMed ID: 28460452
[TBL] [Abstract][Full Text] [Related]
4. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer.
Uehiro N; Sato F; Pu F; Tanaka S; Kawashima M; Kawaguchi K; Sugimoto M; Saji S; Toi M
Breast Cancer Res; 2016 Dec; 18(1):129. PubMed ID: 27993161
[TBL] [Abstract][Full Text] [Related]
5. The diagnostic accuracy of circulating free DNA for the detection of KRAS mutation status in colorectal cancer: A meta-analysis.
Xie W; Xie L; Song X
Cancer Med; 2019 Mar; 8(3):1218-1231. PubMed ID: 30791218
[TBL] [Abstract][Full Text] [Related]
6. The diagnostic accuracy of
Galvano A; Castellana L; Gristina V; La Mantia M; Insalaco L; Barraco N; Perez A; Cutaia S; Calò V; Bazan Russo TD; Francini E; Incorvaia L; Mirisola MG; Vieni S; Rolfo C; Bazan V; Russo A
Ther Adv Med Oncol; 2022; 14():17588359221110162. PubMed ID: 36188485
[TBL] [Abstract][Full Text] [Related]
7. Circulating Cell Free DNA as the Diagnostic Marker for Ovarian Cancer: A Systematic Review and Meta-Analysis.
Zhou Q; Li W; Leng B; Zheng W; He Z; Zuo M; Chen A
PLoS One; 2016; 11(6):e0155495. PubMed ID: 27253331
[TBL] [Abstract][Full Text] [Related]
8. PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA.
Kim ST; Lira M; Deng S; Lee S; Park YS; Lim HY; Kang WK; Mao M; Heo JS; Kwon W; Jang KT; Lee J; Park JO
Oncotarget; 2015 Nov; 6(37):40026-35. PubMed ID: 26498688
[TBL] [Abstract][Full Text] [Related]
9. Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR
Moynahan ME; Chen D; He W; Sung P; Samoila A; You D; Bhatt T; Patel P; Ringeisen F; Hortobagyi GN; Baselga J; Chandarlapaty S
Br J Cancer; 2017 Mar; 116(6):726-730. PubMed ID: 28183140
[TBL] [Abstract][Full Text] [Related]
10. PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients.
Oshiro C; Kagara N; Naoi Y; Shimoda M; Shimomura A; Maruyama N; Shimazu K; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2015 Apr; 150(2):299-307. PubMed ID: 25736040
[TBL] [Abstract][Full Text] [Related]
11. Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer.
Board RE; Wardley AM; Dixon JM; Armstrong AC; Howell S; Renshaw L; Donald E; Greystoke A; Ranson M; Hughes A; Dive C
Breast Cancer Res Treat; 2010 Apr; 120(2):461-7. PubMed ID: 20107891
[TBL] [Abstract][Full Text] [Related]
12. Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients.
Liang DH; Ensor JE; Liu ZB; Patel A; Patel TA; Chang JC; Rodriguez AA
Breast Cancer Res Treat; 2016 Jan; 155(1):139-49. PubMed ID: 26667234
[TBL] [Abstract][Full Text] [Related]
13. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of cell-free DNA in thyroid cancer: A systematic review and meta-analysis.
Hou F; Sun XD; Deng ZY
Medicine (Baltimore); 2023 Feb; 102(7):e32928. PubMed ID: 36800605
[TBL] [Abstract][Full Text] [Related]
15. The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis.
Ibrahim EM; Kazkaz GA; Al-Mansour MM; Al-Foheidi ME
Breast Cancer Res Treat; 2015 Aug; 152(3):463-76. PubMed ID: 26105797
[TBL] [Abstract][Full Text] [Related]
16. Detection of cancer DNA in plasma of patients with early-stage breast cancer.
Beaver JA; Jelovac D; Balukrishna S; Cochran R; Croessmann S; Zabransky DJ; Wong HY; Toro PV; Cidado J; Blair BG; Chu D; Burns T; Higgins MJ; Stearns V; Jacobs L; Habibi M; Lange J; Hurley PJ; Lauring J; VanDenBerg D; Kessler J; Jeter S; Samuels ML; Maar D; Cope L; Cimino-Mathews A; Argani P; Wolff AC; Park BH
Clin Cancer Res; 2014 May; 20(10):2643-2650. PubMed ID: 24504125
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic significance assessment of the circulating cell-free DNA in ovarian cancer: An updated meta-analysis.
Li B; Pu K; Ge L; Wu X
Gene; 2019 Sep; 714():143993. PubMed ID: 31330238
[TBL] [Abstract][Full Text] [Related]
18. Circulating HPV cDNA in the blood as a reliable biomarker for cervical cancer: A meta-analysis.
Gu Y; Wan C; Qiu J; Cui Y; Jiang T; Zhuang Z
PLoS One; 2020; 15(2):e0224001. PubMed ID: 32027658
[TBL] [Abstract][Full Text] [Related]
19. 18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.
Cheng X; Li Y; Liu B; Xu Z; Bao L; Wang J
Acta Radiol; 2012 Jul; 53(6):615-27. PubMed ID: 22734080
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic significance of circulating multiple miRNAs in breast cancer: a systematic review and meta-analysis.
Xie S; Wang Y; Liu H; Wang M; Yu H; Qiao Y; Li F; Xie X; Zhang J
Biomark Med; 2016 Jun; 10(6):661-74. PubMed ID: 27231952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
